Commonwealth Informatics Launches Big Data Offering
Integrated technology platform uses temporal pattern discovery and longitudinal healthcare data to help medical safety teams detect and refine safety signals
Waltham, MA - Commonwealth Informatics, a leading provider of innovative cloud-based products and services for medical product safety and public health surveillance, today announced the general availability of CVW Longitudinal, the first module of the Commonwealth Vigilance Workbench (CVW). CVW is an integrated technology platform designed to help pharmaceutical and biotechnology companies manage a compliant signal management process incorporating analytical evidence for safety from multiple internal and external sources of data.
Recent research efforts by several multi-stakeholder public-private partnerships have demonstrated the value of enhancing safety surveillance systems with analysis of longitudinal healthcare data resources. CVW Longitudinal delivers the statistical methods, insightful graphical displays, and data interfaces needed to apply this research to signal detection and signal refinement for drug and vaccine safety. Building on methods research carried out by the Uppsala Monitoring Centre on “temporal pattern discovery in longitudinal data”, CVW Longitudinal provides the new methods as a packaged software service with the data handling, documentation, support, and security needed for production operations within the regulated pharmaceutical industry. CVW Longitudinal can be used with a wide range of healthcare data sources such as electronic medical records and insurance claims. It provides out-of-the-box analytics for multiple electronic medical record and health insurance claims databases and is cloud-based with no IT infrastructure required.
“The Commonwealth Vigilance Workbench is designed to help safety teams answer complex questions rapidly and accurately. Pharmaceutical and biotechnology companies and government regulatory agencies are looking for ways to efficiently incorporate healthcare data sources into safety signal management. CVW Longitudinal combines innovative signal detection methods with a streamlined user interface allowing teams to rapidly access these rich data sources to more effectively detect, refine and validate potential safety signals that may impact patients,” said Geoff Gordon, Commonwealth President and Founder.
Experience with using CVW Longitudinal was described in two poster presented at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). A team led by Manfred Hauben at Pfizer presented a poster titled: "Signal Detection Using Temporal Pattern Discovery (TPD) in Electronic Health Records (EHRs) - Lessons from Statins and Rhabdomyolysis".
About Commonwealth Informatics
Commonwealth Informatics is a technology and services company with industry expertise in medical product safety and public health surveillance. Pharmaceutical and biotechnology companies, government agencies, and healthcare providers use Commonwealth’s products and services to assemble relevant data and answer complex clinical and safety analysis questions quickly and accurately.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
